• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Risks and benefits of biologic therapy for inflammatory bowel diseases.生物疗法治疗炎症性肠病的风险与益处。
Gut. 2007 May;56(5):725-32. doi: 10.1136/gut.2006.103564.
2
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.炎症性肠病患者使用生物治疗的感染风险。
Clin Pharmacol Ther. 2017 Oct;102(4):633-641. doi: 10.1002/cpt.791. Epub 2017 Aug 16.
3
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.生物疗法与炎症性肠病患者感染和恶性肿瘤风险：系统评价和网络荟萃分析。
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10. doi: 10.1016/j.cgh.2016.04.039. Epub 2016 May 14.
4
Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.孕妇使用生物制剂治疗炎症性肠病不会影响婴儿对疫苗的反应。
Clin Gastroenterol Hepatol. 2018 Jan;16(1):99-105. doi: 10.1016/j.cgh.2017.08.041. Epub 2017 Sep 1.
5
Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease.与生物制剂治疗炎症性肠病相比，使用皮质类固醇治疗炎症性肠病会增加静脉血栓栓塞事件的风险。
Clin Gastroenterol Hepatol. 2016 Jan;14(1):166-7. doi: 10.1016/j.cgh.2015.04.022. Epub 2015 Apr 27.
6
Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.银屑病生物药物治疗中的不良反应：临床系列及文献复习。
G Ital Dermatol Venereol. 2011 Aug;146(4):273-81.
7
The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease.妊娠对炎症性肠病生物治疗的影响。
Best Pract Res Clin Gastroenterol. 2020 Feb-Apr;44-45:101670. doi: 10.1016/j.bpg.2020.101670. Epub 2020 Mar 13.
8
Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease.与生物治疗相比，皮质类固醇治疗炎症性肠病会增加静脉血栓栓塞事件的风险。
Clin Gastroenterol Hepatol. 2015 Feb;13(2):316-21. doi: 10.1016/j.cgh.2014.07.017. Epub 2014 Jul 17.
9
Biologic therapy-induced pemphigus.生物疗法诱发的天疱疮。
An Bras Dermatol. 2017 Jul-Aug;92(4):591-593. doi: 10.1590/abd1806-4841.20176481.
10
Reply.
Clin Gastroenterol Hepatol. 2016 Jan;14(1):167-8. doi: 10.1016/j.cgh.2015.09.012. Epub 2015 Sep 24.

引用本文的文献

1
Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis.大麻二酚增强奥沙拉嗪和环孢素在小鼠结肠炎模型中的治疗效果。
Int J Mol Sci. 2025 Aug 16;26(16):7913. doi: 10.3390/ijms26167913.
2
Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.靶向内源性大麻素系统：一种治疗炎症性肠病肠外并发症的新方法。
Pharmaceuticals (Basel). 2025 Mar 27;18(4):478. doi: 10.3390/ph18040478.
3
Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran.生物疗法治疗溃疡性结肠炎患者的疾病成本分析：伊朗的一项前瞻性观察研究。
BMC Health Serv Res. 2025 Mar 5;25(1):341. doi: 10.1186/s12913-025-12474-6.
4
Medication Burden Before and After Prescription of Biologics in Patients with Inflammatory Bowel Disease.炎症性肠病患者使用生物制剂前后的用药负担
J Clin Med. 2024 Oct 25;13(21):6408. doi: 10.3390/jcm13216408.
5
IL23R-Specific CAR Tregs for the Treatment of Crohn's Disease.用于治疗克罗恩病的白细胞介素23受体特异性嵌合抗原受体调节性T细胞
J Crohns Colitis. 2025 Mar 5;19(3). doi: 10.1093/ecco-jcc/jjae135.
6
Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects.革新胃肠道疾病管理：前沿进展与未来前景
J Clin Med. 2024 Jul 8;13(13):3977. doi: 10.3390/jcm13133977.
7
DNA methylation fine-tunes pro-and anti-inflammatory signalling pathways in inactive ulcerative colitis tissue biopsies.DNA 甲基化精细调节非活动期溃疡性结肠炎组织活检中的促炎和抗炎信号通路。
Sci Rep. 2024 Mar 21;14(1):6789. doi: 10.1038/s41598-024-57440-0.
8
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial.临床药师咨询可改善接受抗 TNF 治疗的炎症性肠病患者的长期用药安全性和患者报告结局：前瞻性、随机 AdPhaNCED 试验
Inflamm Bowel Dis. 2025 Jan 6;31(1):77-86. doi: 10.1093/ibd/izae040.
9
Role of Biologic Therapies in the Rheumatic Manifestations of Inflammatory Bowel Disease: A Systematic Analysis.生物疗法在炎症性肠病风湿表现中的作用：一项系统分析。
Cureus. 2023 Sep 13;15(9):e45195. doi: 10.7759/cureus.45195. eCollection 2023 Sep.
10
Middle small-bowel segment Lewis score may predict long-term outcomes among patients with quiescent Crohn's disease.中段小肠节段Lewis评分可预测静止期克罗恩病患者的长期预后。
Therap Adv Gastroenterol. 2023 Jul 31;16:17562848231188587. doi: 10.1177/17562848231188587. eCollection 2023.

本文引用的文献

1
Risk factors for opportunistic infections in patients with inflammatory bowel disease.炎症性肠病患者机会性感染的危险因素。
Gastroenterology. 2008 Apr;134(4):929-36. doi: 10.1053/j.gastro.2008.01.012. Epub 2008 Jan 11.
2
Higher incidence of abnormal Pap smears in women with inflammatory bowel disease.炎症性肠病女性患者巴氏涂片异常的发生率较高。
Am J Gastroenterol. 2008 Mar;103(3):631-6. doi: 10.1111/j.1572-0241.2007.01582.x. Epub 2007 Oct 17.
3
Infliximab for rheumatoid arthritis in a patient with tuberculosis.英夫利昔单抗用于一名患有结核病的类风湿关节炎患者。
N Engl J Med. 2006 Aug 17;355(7):740-1. doi: 10.1056/NEJMc053468.
4
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.抗CD28单克隆抗体TGN1412 1期试验中的细胞因子风暴
N Engl J Med. 2006 Sep 7;355(10):1018-28. doi: 10.1056/NEJMoa063842. Epub 2006 Aug 14.
5
Infliximab for the treatment of psoriasis.英夫利昔单抗用于治疗银屑病。
Expert Opin Biol Ther. 2006 Aug;6(8):797-805. doi: 10.1517/14712598.6.8.797.
6
Risks and benefits of infliximab for the treatment of Crohn's disease.英夫利昔单抗治疗克罗恩病的风险与益处
Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. doi: 10.1016/j.cgh.2006.05.020. Epub 2006 Jul 14.
7
Anti-tumor necrosis factor-alpha-induced psoriasis.抗肿瘤坏死因子-α诱导的银屑病。
J Rheumatol. 2006 Jul;33(7):1411-4.
8
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.类风湿关节炎中抗 TNF 抗体治疗与严重感染及恶性肿瘤风险：随机对照试验中罕见有害效应的系统评价和荟萃分析
JAMA. 2006 May 17;295(19):2275-85. doi: 10.1001/jama.295.19.2275.
9
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.克罗恩病治疗相关的严重感染与死亡率：TREAT注册研究
Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. doi: 10.1016/j.cgh.2006.03.002.
10
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.1例肝脾γδT细胞淋巴瘤对氟达拉滨和阿仑单抗有短暂反应。
Eur J Haematol. 2006 Jun;76(6):531-4. doi: 10.1111/j.1600-0609.2006.00646.x. Epub 2006 Mar 17.

Risks and benefits of biologic therapy for inflammatory bowel diseases.

作者信息

D'Haens Geert

机构信息

Imelda GI Clinical Research Centre, Imeldalaan 9, 2820 Bonheiden, Belgium.

出版信息

Gut. 2007 May;56(5):725-32. doi: 10.1136/gut.2006.103564.

DOI:10.1136/gut.2006.103564
PMID:17440187
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1942157/
Abstract
摘要